Key Takeaways Boston Scientific's Neuromodulation segment posted 6.8% operational sales growth in Q1 2025. BSX saw strong gains from Intracept, Cartesia leads, and Lumina 3D within pain and brain therapies. Boston Scientific expects continued growth in 2025, aided by Relievant and Axonics acquisitions.Boston Scientific’s (BSX) Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s long-term co ...